港股異動丨國藥控股(1099.HK)漲近6% 國藥集團董事長稱已經做好大規模生產新冠疫苗的準備工作
格隆匯10月21日丨國藥控股(1099.HK)漲近6%,報17.14港元,總市值535億港元。國藥集團董事長昨日表示,目前國內已經開始了緊急使用新冠滅活疫苗,目前中國生物已經做好大規模生產準備工作,能夠保證充足、安全的疫苗供應。昨天召開的國務院聯防聯控機制發佈會帶來重磅消息,當前,我國新冠疫苗研發工作總體處於領先地位,已有13個疫苗進入了臨牀試驗,進入III期臨牀試驗的4個疫苗共計接種約6萬名受試者,未收到嚴重不良反應的報告。預計今年年底,我國新冠疫苗年產能可達6.1億劑,明年產能還將擴大,上市後價格將在大眾可接受的範圍內。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.